Mid-Year Outlook 2026
Our top 10 themes for the year
So far, 2026 has been defined by the geopolitical aftershocks of the US-Israeli military campaign against Iran, which began in late February. The effective closure of the Strait of Hormuz has disrupted energy markets, pushed up inflation expectations and forced markets to reassess the policy path for major central banks. Alongside the geopolitical developments, artificial intelligence demand and the associated bottle-necks have been the key driver for equity market returns.
With this backdrop, we update our core views and translate them into concrete portfolio actions for H2 2026.
Download EFG’s Mid-year Outlook 2026 publication
Outlook 2026Revisit the Outlook 2026 document below
| Download EFG’s Outlook 2026 | |
|---|---|
| Outlook 2026 |
Our top 10 themes for 2026 Mid-Year review
Overall score* for our 2026 predictions:
9/10
The US remains the fastest‑growing major advanced economy in 2026 (IMF 2.3% vs 1.1% eurozone, 0.8% UK, 0.7% Japan), with structural drivers (resilience, growth plan, IT leadership) intact despite the energy shock.
Policy rates did broadly trough as expected, but the Hormuz/energy shock has pushed expectations back up and even raised the risk of renewed tightening; EM high real‑rate opportunities were initially attractive but have become more challenging after the global repricing of rates.
Developed‑market sovereigns, especially the UK, have indeed come under pressure: Gilts have negative YTD returns, yields have spiked to multi‑decade highs and fiscal/political concerns are front and centre, validating the warning on vulnerable sovereigns.
2026 has been dominated by geopolitics (US‑Iran conflict, Hormuz closure, UAE leaving OPEC), a more pragmatic but strategic US‑China stance, deeper US state involvement in strategic sectors, and rising support for more extreme parties in Europe.
Trump’s agenda is clearly market‑relevant, but with a twist: DOGE has largely stalled (savings barely moved from USD 214bn to 215bn), while deregulation and a pro‑innovation FDA stance on drug development are the real ongoing drivers for credit creation and healthcare innovation.
AI has played out as a major secular growth engine: agentic AI is scaling in enterprises, hyperscaler capex has been revised sharply higher, semiconductors face capacity bottlenecks, and a strong IPO/funding pipeline (OpenAI, Anthropic, SpaceXAI) is emerging.
All three pillars are visible: defence spending is rising rapidly, the energy shock is accelerating the green transition under AccelerateEU, and Europe/Switzerland are leaning into innovation, with Switzerland a clear high‑innovation outlier.
EMs have outperformed strongly (MSCI EM up ~25% YTD in local terms, ~15pp over DMs), supported by stronger growth, currency appreciation and AI‑linked markets (Taiwan, Korea), even as the Hormuz shock creates a more nuanced commodity backdrop.
The opportunity set has evolved as expected: mid‑market specialist buyouts and secondaries are outperforming large buyouts, liquidity‑driven secondary deal flow is strong, and private credit/ infrastructure remain key diversifiers in a higher‑for‑longer, more volatile environment.
Activity has normalised with a clear quality bias: fewer IPOs but higher proceeds (SpaceX as the flagship deal), and fewer M&A transactions but the highest Q1 deal value since 2021, consistent with a selective but active deal environment.
* Scoring as at 31 May 2026.